Valuation: ITUS Corp

Market Cap 104M 91.07M 84M 77.58M 147M 9.93B 150M 1B 394M 4.89B 391M 382M 16.82B P/E 2026 *
-9.56x
P/E 2027 * -9x
Enterprise Value 104M 91.07M 84M 77.58M 147M 9.93B 150M 1B 394M 4.89B 391M 382M 16.82B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.69%
Yield 2026 *
-
Yield 2027 * -
07-06 Anixa Biosciences Treats First Patient in Fifth Cohort of Phase 1 Clinical Trial for FSHR-Targeted CAR-T Therapy in Recurrent Ovarian Cancer CI
07-06 Anixa Biosciences Treats First Patient in Fifth Cohort of Ovarian Cancer CAR-T Clinical Trial MT
06-29 Anixa Biosciences Granted Korean Patent for Breast Cancer Vaccine MT
06-26 Anixa Biosciences Presents Final Phase 1 Data For Breast Cancer Vaccine And Positive Survival Observations From Ongoing Ovarian Cancer CAR-T Therapy Trial CI
06-10 Anixa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026 CI
06-01 Anixa Biosciences Says Canadian IP Office Issues Notice of Allowance for Patent Covering Ovarian Cancer Vaccine Technology MT
05-11 Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-Cel Ovarian Cancer Car-T Therapy CI
05-11 Anixa Biosciences reports updated positive survival observations from ongoing phase 1 trial of Lira-Cel ovarian cancer CAR-T therapy RE
04-29 Anixa Biosciences announces issuance of Mexican patent covering breast cancer vaccine technology RE
04-01 Anixa Biosciences, Inc. Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results CI
04-01 Anixa Biosciences advances breast cancer vaccine toward phase 2 after positive phase 1 results; Cytovance selected for cGMP manufacturing RE
03-30 Anixa Biosciences announces presentation of its ovarian cancer CAR-T therapy clinical trial RE
03-09 Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2026 CI
Manager TitleAgeSince
Chief Executive Officer 62 07/07/2017
Director of Finance/CFO 60 01/11/2016
Corporate Officer/Principal 72 07/09/2021
Director TitleAgeSince
Chairman 62 01/08/2016
Chairman 82 01/07/1999
Director/Board Member 77 01/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.84%-0.66%+59.82%+94.48% 54.88B
+0.63%-5.46%+57.69%+131.02% 54.63B
-2.24%+3.59%+17.75%+469.23% 25.06B
-1.60%-6.21%-18.96%-16.06% 23.14B
-1.69%-1.27%+39.51%-8.30% 19.87B
+0.50%+2.76%+36.88%-27.41% 17.55B
-6.84%+2.18%+195.12%+364.56% 16.5B
-2.42%-3.72%+47.02%+635.77% 15.75B
-1.05%+1.16%+25.95%+191.69% 14.2B
Average -1.43%-0.28%+51.20%+203.89% 26.84B
Weighted average by Cap. -0.61%-1.45%+50.51%+173.17%

Financials

2026 *2027 *
Net sales - -
Net income -11M -9.62M -8.87M -8.19M -15.55M -1.05B -15.81M -106M -41.62M -517M -41.28M -40.38M -1.78B -12.28M -10.75M -9.91M -9.15M -17.37M -1.17B -17.66M -118M -46.51M -577M -46.13M -45.12M -1.98B
Net Debt - -
Logo ITUS Corp
Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics program consists of the development of liraltagene autoleucel (lira-cel), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (CAR-T) technology, initially focused on treating ovarian cancer, that is being developed of its subsidiary, Certainty Therapeutics, Inc. (Certainty). Its vaccine programs include the development of a vaccine against breast cancer, the development of a vaccine against ovarian cancer, and a vaccine discovery program utilizing the same mechanism of its breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. It is also developing a method to vaccinate women against breast cancer, focused on triple-negative breast cancer.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-